Advertisement
Advertisement
U.S. markets close in 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tyra Biosciences, Inc. (TYRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.32+0.02 (+0.15%)
As of 02:58PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Diamond Bottom

Diamond Bottom

Previous Close13.30
Open13.75
Bid13.12 x 900
Ask13.34 x 1200
Day's Range12.83 - 13.75
52 Week Range4.93 - 14.61
Volume26,314
Avg. Volume42,995
Market Cap562.069M
Beta (5Y Monthly)N/A
PE Ratio (TTM)18.76
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TYRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Tyra Biosciences, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/22/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

    Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the initiation of its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300. TYRA-300, the Company's lead product candidate stemming from its SNÅP platform, is an oral, FGFR3-selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary

  • PR Newswire

    Tyra Biosciences to Present at Upcoming Investor Conferences

    Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November:

  • PR Newswire

    Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights

    Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended September 30, 2022 and highlighted recent corporate progress.

Advertisement
Advertisement